John Celebi - Feb 15, 2023 Form 4/A - Amendment Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role: President and CEO, Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: SNSE
Transactions as of: Feb 15, 2023
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 3/29/2023, 05:16 PM
Date Of Original Report: Feb 17, 2023
Previous filing: Feb 17, 2022
Next filing: Sep 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNSE	Common Stock	Award	$0	+51.9K	+89.3%	$0.00	110K	Feb 15, 2023	Direct	F1, F2, F3
transaction	SNSE	Common Stock	Award	$0	+21.3K	+19.36%	$0.00	131K	Feb 15, 2023	Direct	F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNSE	Stock Option (Right to Buy)	Award	$0	+90K		$0.00	90K	Feb 15, 2023	Common Stock	90K	$1.43	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP").
F2	These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.
F3	Share balance includes stock purchased under the ESPP not previously reported.
F4	These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F5	The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.